跳转至内容
Merck

PHR1246

Supelco

非诺贝特

Pharmaceutical Secondary Standard; Certified Reference Material

别名:

2- [4-(4-氯苯甲酰)苯氧基]-2-甲基丙酸异丙酯

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C20H21ClO4
CAS号:
分子量:
360.83
EC號碼:
MDL號碼:
分類程式碼代碼:
41116107
PubChem物質ID:
NACRES:
NA.24

等級

certified reference material
pharmaceutical secondary standard

品質等級

agency

traceable to Ph. Eur. F0048000
traceable to USP 1269447

API 家族

fenofibrate

CofA

current certificate can be downloaded

技術

HPLC: suitable
gas chromatography (GC): suitable

應用

pharmaceutical (small molecule)

形式

neat

儲存溫度

2-8°C

SMILES 字串

CC(C)OC(=O)C(C)(C)Oc1ccc(cc1)C(=O)c2ccc(Cl)cc2

InChI

1S/C20H21ClO4/c1-13(2)24-19(23)20(3,4)25-17-11-7-15(8-12-17)18(22)14-5-9-16(21)10-6-14/h5-13H,1-4H3

InChI 密鑰

YMTINGFKWWXKFG-UHFFFAOYSA-N

基因資訊

human ... PPARA(5465)

正在寻找类似产品? 访问 产品对比指南

一般說明

Pharmaceutical secondary standards for application in quality control, provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards.
Fenofibrate is a third-generation fibric acid derivative which is widely employed for the treatment of atherogenic dyslipidemia, hypertriglyceridemia, mixed dyslipidemia and hypercholesterolemia.

應用

Fenofibrate may be used as a pharmaceutical reference standard for the determination of the analyte in pharmaceutical formulations by various chromatography and spectrophotometry techniques.
These Secondary Standards are qualified as Certified Reference Materials. These are suitable for use in several analytical applications including but not limited to pharma release testing, pharma method development for qualitative and quantitative analyses, food and beverage quality control testing, and other calibration requirements.

分析報告

These secondary standards offer multi-traceability to the USP, EP (PhEur) and BP primary standards, where they are available.

其他說明

This Certified Reference Material (CRM) is produced and certified in accordance with ISO 17034 and ISO/IEC 17025. All information regarding the use of this CRM can be found on the certificate of analysis.

腳註

To see an example of a Certificate of Analysis for this material enter LRAC0257 in the slot below. This is an example certificate only and may not be the lot that you receive.

推薦產品

Find a digital Reference Material for this product available on our online platform ChemisTwin® for NMR. You can use this digital equivalent on ChemisTwin® for your sample identity confirmation and compound quantification (with digital external standard). An NMR spectrum of this substance can be viewed and an online comparison against your sample can be performed with a few mouseclicks. Learn more here and start your free trial.

象形圖

Health hazard

訊號詞

Warning

危險聲明

防範說明

危險分類

STOT RE 2 Oral

標靶器官

Liver

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 1

閃點(°F)

Not applicable

閃點(°C)

Not applicable


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Simultaneous Estimation of Rosuvastatin Calcium and Fenofibrate in Bulk and in Tablet Dosage Form by UV-Spectrophotometry and RP-HPLC
Karunakaran A, et al.
Stamford Journal of Pharmaceutical Sciences, 4(1), 58-63 (2011)
Estimation of Atorvastatin Calcium and Fenofibrate in Tablets by Derivative Spectrophotometry and Liquid Chromatography
Nakarani NV, et al.
Journal of AOAC (Association of Official Analytical Chemists) International, 90(3), 700-705 (2007)
Electrochemical studies and square-wave voltammetric determination of fenofibrate in pharmaceutical formulations
Yardimci C and Ozaltin N
Analytical and Bioanalytical Chemistry, 378(2), 495-498 (2004)
Stanley M H Chan et al.
Diabetes, 62(6), 2095-2105 (2013-01-26)
Endoplasmic reticulum (ER) stress is suggested to cause hepatic insulin resistance by increasing de novo lipogenesis (DNL) and directly interfering with insulin signaling through the activation of the c-Jun N-terminal kinase (JNK) and IκB kinase (IKK) pathway. The current study
Cordula Stillhart et al.
The Journal of pharmacy and pharmacology, 65(2), 181-192 (2013-01-03)
To advance in vitro screening of surfactant/co-solvent formulations in early development by considering drug supersaturation and the mechanism of solubilization upon aqueous dilution. Two surfactant/co-solvent model systems were studied at practically relevant aqueous dilution ratios. Precipitation of the model drug

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门